Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the Americas, Europe, the Middle East, and Africa.
Trajan Group Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$3.00|
|52 Week High||AU$1.82|
|52 Week Low||AU$3.60|
|1 Month Change||-9.09%|
|3 Month Change||12.78%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||51.52%|
Recent News & Updates
|TRJ||AU Life Sciences||AU Market|
Return vs Industry: Insufficient data to determine how TRJ performed against the Australian Life Sciences industry.
Return vs Market: Insufficient data to determine how TRJ performed against the Australian Market.
Stable Share Price: TRJ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: Insufficient data to determine TRJ's volatility change over the past year.
About the Company
Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the Americas, Europe, the Middle East, and Africa. It offers analytical, pathology, and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance.
Trajan Group Holdings Fundamentals Summary
|TRJ fundamental statistics|
Is TRJ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TRJ income statement (TTM)|
|Cost of Revenue||AU$48.08m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.014|
|Net Profit Margin||2.46%|
How did TRJ perform over the long term?See historical performance and comparison
Is Trajan Group Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TRJ (A$3) is trading below our estimate of fair value (A$3.58)
Significantly Below Fair Value: TRJ is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: TRJ is poor value based on its PE Ratio (207.3x) compared to the Global Life Sciences industry average (46x).
PE vs Market: TRJ is poor value based on its PE Ratio (207.3x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: TRJ is poor value based on its PEG Ratio (5.7x)
Price to Book Ratio
PB vs Industry: TRJ is overvalued based on its PB Ratio (5.9x) compared to the AU Life Sciences industry average (4.9x).
How is Trajan Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRJ's forecast earnings growth (36.2% per year) is above the savings rate (1.9%).
Earnings vs Market: TRJ's earnings (36.2% per year) are forecast to grow faster than the Australian market (11.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TRJ's revenue (11% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: TRJ's revenue (11% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TRJ's Return on Equity is forecast to be low in 3 years time (12.2%).
How has Trajan Group Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRJ has a large one-off gain of A$1.9M impacting its June 30 2021 financial results.
Growing Profit Margin: TRJ's current net profit margins (2.5%) are lower than last year (3.6%).
Past Earnings Growth Analysis
Earnings Trend: TRJ's earnings have grown significantly by 25.8% per year over the past 5 years.
Accelerating Growth: TRJ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TRJ had negative earnings growth (-27.9%) over the past year, making it difficult to compare to the Life Sciences industry average (59.8%).
Return on Equity
High ROE: TRJ's Return on Equity (2.8%) is considered low.
How is Trajan Group Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: TRJ's short term assets (A$78.5M) exceed its short term liabilities (A$24.1M).
Long Term Liabilities: TRJ's short term assets (A$78.5M) exceed its long term liabilities (A$9.2M).
Debt to Equity History and Analysis
Debt Level: TRJ's debt to equity ratio (11%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TRJ's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: TRJ's debt is well covered by operating cash flow (129.5%).
Interest Coverage: Insufficient data to determine if TRJ's interest payments on its debt are well covered by EBIT.
What is Trajan Group Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRJ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRJ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRJ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Stephen Tomisich serves as Chief Executive Officer, Managing Director and Director at Trajan Group Holdings Limited. Mr. Tomisich serves as Chief Executive Officer and Director at Trajan Scientific & M...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD386.28K) is below average for companies of similar size in the Australian market ($USD556.28K).
Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TRJ only recently listed within the past 12 months.
Trajan Group Holdings Limited's employee growth, exchange listings and data sources
- Name: Trajan Group Holdings Limited
- Ticker: TRJ
- Exchange: ASX
- Founded: 2011
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$389.715m
- Shares outstanding: 129.90m
- Website: https://www.trajanscimed.com
Number of Employees
- Trajan Group Holdings Limited
- 7 Argent Place
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:40|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.